Contact
Please use this form to send email to PR contact of this press release:
Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome
TO:
Please use this form to send email to PR contact of this press release:
Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome
TO: